110,279 Shares in Bristol-Myers Squibb (NYSE:BMY) Acquired by Bcwm LLC

Bcwm LLC bought a new position in shares of Bristol-Myers Squibb (NYSE:BMY) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 110,279 shares of the biopharmaceutical company’s stock, valued at approximately $6,237,000. Bristol-Myers Squibb accounts for 2.2% of Bcwm LLC’s portfolio, making the stock its 20th largest holding.

Several other institutional investors and hedge funds also recently made changes to their positions in BMY. United Bank increased its holdings in Bristol-Myers Squibb by 16.9% in the fourth quarter. United Bank now owns 20,242 shares of the biopharmaceutical company’s stock valued at $1,145,000 after purchasing an additional 2,920 shares during the last quarter. CIBC Private Wealth Group LLC increased its stake in shares of Bristol-Myers Squibb by 3.7% in the 4th quarter. CIBC Private Wealth Group LLC now owns 307,582 shares of the biopharmaceutical company’s stock valued at $17,474,000 after acquiring an additional 11,057 shares during the last quarter. Summit Securities Group LLC raised its position in shares of Bristol-Myers Squibb by 1,968.0% in the 4th quarter. Summit Securities Group LLC now owns 51,700 shares of the biopharmaceutical company’s stock valued at $2,924,000 after acquiring an additional 49,200 shares during the period. Portland Global Advisors LLC boosted its stake in Bristol-Myers Squibb by 7.2% during the 4th quarter. Portland Global Advisors LLC now owns 5,419 shares of the biopharmaceutical company’s stock worth $306,000 after acquiring an additional 365 shares during the last quarter. Finally, Schroder Investment Management Group grew its holdings in Bristol-Myers Squibb by 49.7% during the fourth quarter. Schroder Investment Management Group now owns 11,413,428 shares of the biopharmaceutical company’s stock valued at $639,837,000 after purchasing an additional 3,787,075 shares during the period. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Up 2.0 %

Shares of Bristol-Myers Squibb stock opened at $60.10 on Friday. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The business’s 50 day moving average is $58.55 and its 200-day moving average is $56.30. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33. The stock has a market cap of $121.96 billion, a P/E ratio of -13.60, a P/E/G ratio of 2.07 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. Equities research analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be paid a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.13%. The ex-dividend date is Friday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is presently -56.11%.

Insider Activity at Bristol-Myers Squibb

In other news, EVP Samit Hirawat bought 1,823 shares of the firm’s stock in a transaction dated Friday, February 14th. The shares were bought at an average price of $54.84 per share, with a total value of $99,973.32. Following the completion of the transaction, the executive vice president now owns 63,932 shares of the company’s stock, valued at $3,506,030.88. This trade represents a 2.94 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.09% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BMY. Truist Financial boosted their price target on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Jefferies Financial Group raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and boosted their target price for the company from $63.00 to $70.00 in a research note on Monday, December 16th. Bank of America reiterated a “neutral” rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th. Wells Fargo & Company increased their target price on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a research note on Friday, February 7th. Finally, Citigroup upped their price target on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating, four have given a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $57.86.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.